文献速递乳腺癌

前瞻性多中心随机III期试验评估淋巴显像作为早期乳腺癌前哨淋巴结活检组成部分的影响:SenSzi(GBG80)试验

Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial.
PubMed 文献 · J Clin Oncol · 2019-05-01

这项前瞻性多中心随机III期试验纳入cN0早期乳腺癌或广泛/高级别导管原位癌患者,随机分配至前哨淋巴结活检(SLNB)时知晓或不知晓术前淋巴显像(LSG)结果。改良意向治疗分析(n=1163)显示两组组织学检出前哨淋巴结均数分别为2.21(知晓LSG)和2.26(不知晓LSG),差异0.05(分层95%CI,-0.18至无穷),证实省略术前LSG的非劣效性;次要终点无统计学显著差异。结论:SLNB效果与术者是否知晓术前LSG结果无关,省略LSG可加速术前流程并降低成本。

要点

  • SLNB时不知晓术前LSG结果的组织学检出前哨淋巴结均数为2.26,知晓LSG组为2.21,差异0.05(分层95%CI,-0.18至无穷),达到非劣效。
  • 省略术前LSG不会影响淋巴结转移的可靠检出,次要终点(淋巴结阳性率和完成腋窝淋巴结清扫率)无统计学显著差异。
  • SLNB无需依赖术前LSG结果,可加速术前工作流程并降低费用。

核心结论

  • SLNB的效果与术者是否知晓术前LSG结果无关,省略LSG可加速术前流程并降低成本。

研究设计与样本

  • 前瞻性、多中心、随机III期试验,2014年5月至2015年10月在23家德国和瑞士乳腺癌中心随机分配1198例cN0早期乳腺癌或广泛/高级别导管原位癌计划行标准放射性标记胶体LSG及后续SLNB的患者。
  • 患者按1:1随机分配至SLNB时知晓或不知晓LSG结果,按肿瘤灶性和试验中心分层。
  • 改良意向治疗分析纳入1163例患者。

主要发现

  • 组织学检出前哨淋巴结均数:知晓LSG组2.21 vs 不知晓LSG组2.26,差异0.05(分层95%CI,-0.18至无穷),证实省略术前LSG的非劣效性。
  • 次要终点(淋巴结阳性患者率和完成腋窝淋巴结清扫率)显示无统计学显著差异。

关键数值与推荐

  • 非劣效界值为10%,分层单侧95%CI下限须大于-0.27。
  • 主要终点组织学检出前哨淋巴结均数差异0.05(分层95%CI,-0.18至无穷),达到非劣效。

临床怎么用

  • SLNB可在不知晓术前LSG结果的情况下进行,效果与知晓LSG结果时相当。
  • 省略术前LSG可加速术前工作流程并降低费用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of the current work was to clarify whether a preoperative lymphoscintigraphy (LSG) enhances staging accuracy of sentinel lymph node biopsy (SLNB). PATIENTS AND METHODS: In a prospective, multicenter, randomized phase III trial, patients with cN0 early breast cancer or extensive/high-grade ductal carcinoma in situ planned for standard radioactive-labeled colloid LSG with subsequent SLNB were randomly assigned 1:1 to receive SLNB either with knowledge of the LSG findings or without. As the false-negative rate of SLNB correlates with the number of resected sentinel lymph nodes (SLNs), our primary end point was the mean number of histologically detected SLNs per patient. One thousand one hundred two evaluable patients were necessary to demonstrate noninferiority of SLNB without LSG. Stratified one-sided 95% CI for the difference (without LSG - with LSG) in the mean number of histologically detected SLNs had to be greater than -0.27 (10% noninferiority margin). Stratification was performed according to tumor focality and trial site. Additional predefined secondary end points (rates of node-positive patients and of completion axillary lymph node dissection) were analyzed to rule out differences in the reliable detection of nodal metastases. RESULTS: Between May 2014 and October 2015, 1,198 patients were randomly assigned in 23 German and Swiss breast centers. Modified intention-to-treat analysis (n = 1,163) showed a mean number of histologically detected SLNs of 2.21 with LSG and 2.26 without LSG (difference 0.05; stratified 95% CI, -0.18 to infinity), thus establishing noninferiority of omitting preoperative LSG. Secondary end points displayed no statistically significant differences. CONCLUSION: We show that SLNB is equally effective irrespective of the surgeon's knowledge of preoperative LSG results. SLNB without LSG will speed up the preoperative workflow and reduce cost.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kuemmel S, Holtschmidt J, Gerber B, et al. Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial. J Clin Oncol. 2019. PMID: 31042410. doi:10.1200/JCO.18.02092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。